About
KNOW-HOW
Kurt and Andreas are serial entrepreneurs with many years of experience in the biotech and pharmaceutical industry. With our expert knowledge, we help shape the long-term development of our portfolio companies and provide them with access to a broad investor and business network. By doing so, we support exceptional entrepreneurs in their quest to accelerate medical breakthrough.
CAPITAL
Ventura Biomed Investors typically invests EUR 1 – 5 million per company, always in consortia with other funds and within Europe. To increase our impact and reach, we can furthermore invest via our investment platform Ventura Ace, which comprises selected, renowned private investors. For both Ventura Biomed Investors and Ventura Ace, our investment focus is on early-stage life science companies developing pioneering technologies and innovative therapies.
LEADERSHIP
Dr. Andreas Jenne
Andreas has launched several biotech companies, which he managed in leading positions. Among others, he was CEO of Kinaxo, a proteomics service provider that was acquired by Evotec, and NEO New Oncology, a cancer diagnostics company that was bought by Siemens Healthcare.
In addition to his investment activities, he is an active board member in various biotech and medtech companies. Andreas holds a Ph.D. in Chemistry from the Ludwig-Maximilians-University in Munich.
Dr. Kurt Rudolf Schwarz
Kurt is an active investor and business angel. Besides investing in all major asset classes, he is engaged in numerous health care companies. Furthermore, he is an active member in a variety of cultural, philanthropic and political institutions.
Kurt was member of the supervisory board of Schwarz Pharma, where he represented the Schwarz family as a major shareholder. Other professional affiliations include Merck & Co. as well as Harvard Medical School and Massachusetts General Hospital where he worked as a scientist and physician.
Photos by Caro Dirscherl carodirscherl.de